FMP
Anebulo Pharmaceuticals, Inc.
ANEB
NASDAQ
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
2.7 USD
0.0336 (1.24%)
About
ceo
Mr. Richard Anthony Cunningham
sector
Healthcare
industry
Biotechnology
website
https://www.anebulo.com
exchange
NASDAQ
Description
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
CIK
0001815974
ISIN
US0345691036
CUSIP
034569103
Address
1415 Ranch Road 620 South
Phone
512 598 0931
Country
US
Employee
2
IPO Date
May 7, 2021
Key Executives
